COMMUNIQUÉS West-GlobeNewswire

Mustang Bio to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018

14/12/2017 - 13:30

NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO ), a Fortress Biotech (NASDAQ: FBIO ) company focused on the development of novel immunotherapies based on proprietary chimeric [...]

Fortress Biotech to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018

14/12/2017 - 13:30

NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (“Fortress”) (NASDAQ: FBIO ), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]

Strongbridge Biopharma plc Announces New Employment Inducement Awards

14/12/2017 - 13:30

DUBLIN, Ireland and TREVOSE, Pa., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP ), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]

Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018

14/12/2017 - 13:30

NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT ), a Fortress Biotech (NASDAQ: FBIO ) company, today announced that its senior management team will host [...]

Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors

14/12/2017 - 13:01

BEDMINSTER, N.J., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, [...]

Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

14/12/2017 - 13:00

-- Successfully Completed Initial Public Offering, Raising $74.9 Million in Gross Proceeds -- Presented Final Results from Phase 2 Trials of ALLN-177 in Secondary Hyperoxaluria at ASN Kidney Week 2017 -- Received Orphan [...]

Jounce Therapeutics Added to NASDAQ Biotechnology Index

14/12/2017 - 13:00

CAMBRIDGE, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE ), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers [...]

Microbot Receives Notice of Allowance for U.S. Patent Covering its TipCAT Technology Platform

14/12/2017 - 13:00

HINGHAM, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT ), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today [...]

Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation

14/12/2017 - 13:00

Builds on preclinical research conducted at Duke University and clinical research conducted by Axsome Smoking cessation is the third indication for AXS-05 Phase 2 trial initiation anticipated in the first quarter of [...]

HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data

14/12/2017 - 13:00

WATERTOWN, Mass. and NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in the development of sustained release drug delivery products, and Hospital for Special Surgery (HSS), [...]

Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)

14/12/2017 - 13:00

CAMBRIDGE, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious [...]

Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart Failure

14/12/2017 - 12:30

IRVINE, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), a fully integrated, science-based, nutraceutical company devoted to improving the way people age, announced important cardiac research [...]

Kraig Biocraft Laboratories Begins Operations in New Laboratory

14/12/2017 - 12:05

ANN ARBOR, Mich., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company has completed the build [...]

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...

14/12/2017 - 11:31

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l' [...]

Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...

14/12/2017 - 11:31

Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]

Norrlandsfonden begär konvertering av utestående konvertibellån

14/12/2017 - 08:30

C-RAD har under perioden 2006 – 2013 ställt ut konvertibla skuldebrev till Norrlandsfonden. Samtliga skuldebrev har en löptid t o m 31 januari 2018 om inte konvertering dessförinnan påkallats av konvertibelägare. C-RAD [...]

Issuance of shares pursuant to the restricted share unit reward plan

14/12/2017 - 08:01

Company announcement, Helsinki, 14 December 2017, at 9 am Issuance of shares pursuant to the restricted share unit reward plan Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or the " Company "), a medical technology [...]

Proteostasis Therapeutics Prices Public Offering of Common Stock

14/12/2017 - 02:31

CAMBRIDGE, Mass., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI ), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to [...]

argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering

14/12/2017 - 01:27

Regulated information - Inside information Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody- [...]